Clinical trials: Depression Acute
Depression
Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit
This study will determine the effectiveness of antidepressant medication in preventing depression and improving recovery in people who have been supported by mechanical ventilators in an intensive care unit (ICU).
- Trial name
- NCT00872027
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Minnesota
Cardiovascular Diseases, Acute Coronary Syndrome
MBCT Via Group Videoconferencing for Acute Coronary Syndrome Patients With Depressive Symptoms: A Pilot RCT
The aim of this study is to establish, in a pilot RCT (approx. N=50 participants) with a time- and attention-matched health enhancement control, (a) the feasibility of the recruitment procedures (screening, eligibility…
- Conditions
- Cardiovascular Diseases, Acute Coronary Syndrome, Depression
- Trial name
- NCT04799899
- Testing
- Adapted MBCT, Cardiac Health Enhancement
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Depression, Acute Pain
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)
This is a Master Protocol Screening record. This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design.
- Conditions
- Depression, Acute Pain, Chronic Pain
- Trial name
- ADOPT PGx (NCT04445792)
- Testing
- Pharmacogenetic testing, Clinical decisions support
- Where
- 14 sites in United States
- Volunteers
- 4,284 people
- Sponsor
- Duke University
Acute Pain
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial)
This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design.
- Trial name
- ADOPT PGx (NCT05966129)
- Testing
- Pharmacogenetic testing, Clinical decisions support
- Where
- 11 sites in United States
- Volunteers
- 1,602 people
- Sponsor
- Duke University
Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute
Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration
The investigators are conducting a randomized controlled trial to assess the impact of Resiliency in Stressful Experiences (RISE) - a comprehensive trauma-based program for young men releasing from a southeastern state's prisons.
- Conditions
- Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute, Depressive Symptoms, Anxiety
- Trial name
- NCT04785677
- Testing
- Resiliency in Stressful Experiences (RISE) Program
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Florida State University
Heart Diseases, Depression
COPES Phase I Randomized Controlled Trial of Treatment For Distress in Heart Disease Patients
The specific aim of the "Coronary Patients Evaluation Study" (COPES) Project 2 is, within a Phase-I RCT, to examine patient satisfaction, treatment safety, and symptom reduction associated with treatment for symptoms of distress…
- Trial name
- NCT00158054
- Testing
- Enhanced depression care, Referred depression care
- Where
- 3 sites in United States
- Volunteers
- 157 people
- Sponsor
- Columbia University
Depression, Suicide
Ketamine for Depression and Suicide Risk
The purpose of this research study was to find out if the medication known as ketamine could help the symptoms of depression. This drug is approved by the U.S.
- Trial name
- Ketamine (NCT02094898)
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Obstetric Pain, Postpartum Depression
Ketamine to Improve Recovery After Cesarean Delivery - Part 1
The objective of this study is evaluate the breastmilk transfer and pharmacokinetics (Part 1) and effectiveness (Part 2) of a post-cesarean delivery intravenous ketamine bolus-and-infusion strategy, as a preventive analgesic…
- Conditions
- Obstetric Pain, Postpartum Depression, Breastfeeding, Pain, Acute
- Trial name
- KINETIC (NCT04037085)
- Testing
- Ketamine
- Where
- 2 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Grace Lim, MD, MS
Intensive Care Unit Survivors, Informal Caregivers (Family and Friends)
Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers
Patients who receive life support in intensive care units commonly suffer from persistent depression, anxiety, and post-traumatic stress disorder (PTSD) symptoms after discharge.
- Trial name
- NCT01983254
- Testing
- coping skills training, education program
- Where
- 4 sites in United States
- Volunteers
- 417 people
- Sponsor
- Duke University
Depressive Disorder, Major
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01153009
- Testing
- Vortioxetine, Duloxetine
- Where
- 56 sites in United States
- Volunteers
- 614 people
- Sponsor
- Takeda
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Vortioxetine in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder…
- Trial name
- NCT00635219
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 766 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.
- Trial name
- NCT00735709
- Testing
- Vortioxetine
- Where
- 48 sites in Australia, Czechia and 13 more
- Volunteers
- 560 people
- Sponsor
- Takeda
Bipolar Disorder
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who…
- Trial name
- NCT00490971
- Testing
- Olanzapine, Paliperidone ER
- Where
- 78 sites in United States, Bulgaria and 14 more
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
A Study in Depression and Associated Painful Physical Symptoms
The purpose of this study is to find out if 60 mg of duloxetine given once a day by mouth for 8 weeks to patients diagnosed with major depressive disorder, who also report associated painful physical symptoms, is better than…
- Trial name
- NCT01070329
- Testing
- Duloxetine
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 527 people
- Sponsor
- Eli Lilly and Company
Bipolar Depression
Ceftriaxone in the Management of Bipolar Depression
We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to…
- Trial name
- NCT00566111
- Testing
- ceftriaxone, Saline solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Respiratory Insufficiency, Depression
Behavioral Activation-Rehabilitation to Improve Depressive Symptoms & Physical Function After Acute Respiratory Failure
More and more people are surviving after receiving life support for respiratory failure in the intensive care unit, but these patients often experience problems with depression and physical functioning that lead to reduced…
- Conditions
- Respiratory Insufficiency, Depression, Rehabilitation, Critical Care
- Trial name
- BEHAB (NCT03431493)
- Testing
- Behavioral Activation - Rehabilitation
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Johns Hopkins University
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients
To assess the efficacy of Vortioxetine (5 mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale (HAM-D24) total score after 8 weeks of…
- Trial name
- NCT00811252
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Psychotic Depression
The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression
The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.
- Trial name
- Abilify (NCT00556140)
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Bipolar Depression
Efficacy of rTMS in Bipolar Depression
Bipolar Disorder is a common condition that is characterized by periods of mood elevation however periods of chronic and recurring depressive episodes are more common and can be severely disabling.
- Trial name
- rTMS-BD (NCT02749006)
- Testing
- iTBS repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- University of British Columbia
Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD.
- Conditions
- Anti-Psychotic, Management of Manifestations of Psychotic Disorders, Treatment of Schizophrenia, Control Nausea and Vomiting
- Trial name
- NCT02943213
- Testing
- Chlorpromazine Hydrochloride
- Where
- South Africa
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.